m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03207)
Name
IRX-5183
Synonyms
AGN-195183; NRX-195183; NRX-5183; VTP-195183; VTP-5183; IRX-5183 (oral, autoimmune disease), Io Therapeutics; RARa (oral, cancer/autoimmune disease), Io Therapeutics; RARa agonist (topical, skin/eye diseases), Io Therapeutics; Retinoic acid receptor alpha agonist (oral, cancer/autoimmune disease), Io Therapeutics; Retinoic acid receptor alpha agonist (topical, skin/eye diseases), Io Therapeutics; IRX-5183 (oral, cancer/autoimmune disease), Io Therapeutics; IRX-5183 (topical, skin/eye diseases), Io Therapeutics
    Click to Show/Hide
Status
Phase 1
Structure
Formula
C22H22ClF2NO4
InChI
1S/C22H22ClF2NO4/c1-21(2)5-6-22(3,4)16-12(21)9-11(18(27)17(16)23)19(28)26-10-7-13(24)15(20(29)30)14(25)8-10/h7-9,27H,5-6H2,1-4H3,(H,26,28)(H,29,30)
InChIKey
PNAWUIKCVQSLFG-UHFFFAOYSA-N
PubChem CID
9867758
TTD Drug ID
D0T3DO
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Retinoic acid receptor alpha (RARA)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Retinoic acid receptor alpha (RARA) is a therapeutic target for IRX-5183. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of IRX-5183 through regulating the expression of Retinoic acid receptor alpha (RARA). [1], [2]
References
Ref 1 FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N(6)-Methyladenosine RNA Demethylase. Cancer Cell. 2017 Jan 9;31(1):127-141. doi: 10.1016/j.ccell.2016.11.017. Epub 2016 Dec 22.
Ref 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)